CDEK by Data4ThePeople

Sign in Sign up

← All organizations

Bellerophon Therapeutics

For profitWebsite ↗

Also known as: Acting Chief Medical Officer | Bellerophon | Bellerophon Pulse Technologies | Bellerophon Therapeutics | Bellerophon Therapeutics (consultant) | Bellerophon Therapuetics

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

Last known activity

Jul 1, 2020

Timeline

2000s

Jun 1, 2009
Bellerophon Therapeutics— Founded

Drugs by trial phase (4 distinct, 14 trials)

Phase 3 (1 own, 0 via acquisition)

nitric oxide

Phase 2 (3 own, 0 via acquisition)

Indications

Studied for

Recent trials (23)

NCT04358588Lead sponsorN/A—
NCT04358588Study directorN/A—
NCT04398290CollaboratorPhase 2Jul 1, 2020
NCT04388683CollaboratorPhase 2May 12, 2020
NCT03873298CollaboratorPhase 2Mar 4, 2019
NCT03727451Study directorPhase 2Jan 30, 2019
NCT03727451Lead sponsorPhase 2Jan 30, 2019
NCT03602781Lead sponsorPhase 3Aug 31, 2018
NCT03602781Study directorPhase 3Aug 31, 2018
NCT03267108CollaboratorPhase 2Dec 29, 2017
NCT05747508Lead sponsorPhase 2Dec 29, 2017
NCT03267108Lead sponsorPhase 2Dec 29, 2017
NCT05747508Study directorPhase 2Dec 29, 2017
NCT03267108Study directorPhase 2Dec 29, 2017
NCT03135860Study chairEarly Phase 1Oct 1, 2016

Details

Founded: Warren, NJ, US Jun 1, 2009
Last known activity: Jul 1, 2020